1. Home
  2. HIPO vs XERS Comparison

HIPO vs XERS Comparison

Compare HIPO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HIPO
  • XERS
  • Stock Information
  • Founded
  • HIPO 2015
  • XERS 2005
  • Country
  • HIPO United States
  • XERS United States
  • Employees
  • HIPO N/A
  • XERS N/A
  • Industry
  • HIPO Property-Casualty Insurers
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • HIPO Finance
  • XERS Health Care
  • Exchange
  • HIPO Nasdaq
  • XERS Nasdaq
  • Market Cap
  • HIPO 440.1M
  • XERS 500.2M
  • IPO Year
  • HIPO N/A
  • XERS 2018
  • Fundamental
  • Price
  • HIPO $26.65
  • XERS $3.34
  • Analyst Decision
  • HIPO Buy
  • XERS Buy
  • Analyst Count
  • HIPO 3
  • XERS 3
  • Target Price
  • HIPO $28.00
  • XERS $4.87
  • AVG Volume (30 Days)
  • HIPO 166.8K
  • XERS 1.3M
  • Earning Date
  • HIPO 03-05-2025
  • XERS 03-05-2025
  • Dividend Yield
  • HIPO N/A
  • XERS N/A
  • EPS Growth
  • HIPO N/A
  • XERS N/A
  • EPS
  • HIPO N/A
  • XERS N/A
  • Revenue
  • HIPO $334,700,000.00
  • XERS $187,361,000.00
  • Revenue This Year
  • HIPO N/A
  • XERS $24.27
  • Revenue Next Year
  • HIPO $22.09
  • XERS $18.57
  • P/E Ratio
  • HIPO N/A
  • XERS N/A
  • Revenue Growth
  • HIPO 84.92
  • XERS 22.72
  • 52 Week Low
  • HIPO $8.68
  • XERS $1.69
  • 52 Week High
  • HIPO $34.24
  • XERS $3.87
  • Technical
  • Relative Strength Index (RSI)
  • HIPO 49.44
  • XERS 49.66
  • Support Level
  • HIPO $22.83
  • XERS $3.14
  • Resistance Level
  • HIPO $28.38
  • XERS $3.60
  • Average True Range (ATR)
  • HIPO 1.31
  • XERS 0.17
  • MACD
  • HIPO 0.13
  • XERS -0.02
  • Stochastic Oscillator
  • HIPO 68.78
  • XERS 37.74

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the Company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Share on Social Networks: